USANA Updates Fiscal 2026 Outlook
The company now expects net sales approaching $900 million and adjusted EBITDA of about $77 million, with weaker expectations for its Rise Wellness business.
Updated on Nov. 5, 2026 in Healthcare
USANA Health Sciences updated its fiscal 2026 outlook, projecting consolidated net sales approaching $900 million and adjusted EBITDA of about $77 million. The company also lowered its Rise Wellness outlook again, while stronger profitability in Core Nutritional partly offset those pressures.
Why it matters
The revised outlook reflects softer expectations for Rise Wellness and marketing investment in Hiya, signaling that growth is currently being pursued at the expense of near-term margins. Management has identified customer growth as its top priority going forward.
The updated outlook projects consolidated net sales approaching $900 million and adjusted EBITDA of about $77 million, with the current Hiya sales outlook at $130 million. Hiya's active monthly subscribers grew 18% sequentially, while USANA's active customer count fell 8% year over year, with the declines concentrated in Greater China.
The players
USANA Health Sciences
A publicly traded direct-selling nutritional supplement company that markets health and wellness products through independent distributors worldwide.
The details
Greater China accounted for most of the sequential declines in sales and customers. Management has identified customer growth as its top priority, and the company's Hiya subscription business gained subscribers during the period even as overall active customers fell.
Timeline
Fiscal 2026: USANA updated its outlook for the year.
November 5, 2026: Reporting on the updated outlook was published.
Market Landscape
Direct-selling nutritional companies depend heavily on active customer counts, so a year-over-year decline in customers signals pressure on the core model. USANA's push to grow customers through marketing spend in its Hiya subscription line places it in a competitive effort to rebuild that base.
Customers of USANA's Hiya subscription line are seeing continued growth in subscribers, which reflects the company's marketing investment. Shoppers and distributors should watch whether the company's customer-growth priority stabilizes the decline in its active customer count.
The takeaway
Investors and customers should track whether USANA's marketing spend on Hiya converts subscriber growth into a recovery in its overall active customer base. The next outlook update will show whether the Rise Wellness downgrade and margin trade-offs are holding.
Further reading
Explore more coverage in the Healthcare section of our business news.
Source note: This article includes information reported by TokenPost.
